Takeda Pharmaceutical Q1 2025 Earnings Report

SEC Filing 6-K (0001395064-25-000120)

Takeda Pharmaceutical Company Limited reported its financial results for the three-month period ended June 30, 2025. The company's revenue for the quarter was JPY 1,106.7 billion, a decrease of 8.4% compared to the same period in 2024. Operating profit increased by 11.0% to JPY 184.6 billion, while net profit attributable to owners of the company rose by 30.4% to JPY 124.2 billion. The decline in revenue was primarily due to unfavorable foreign exchange rates and a decrease in revenue in the Neuroscience business area, largely driven by generic erosion of VYVANSE in the U.S. Takeda also provided its full-year forecast for the fiscal year ending March 31, 2026, projecting a slight decrease in revenue but significant increases in operating profit and net profit. The company emphasized that its forecasts are based on current information and assumptions and are subject to various uncertainties, including changes in the business environment and foreign exchange rate fluctuations.